Evaluation of oxytocin (OXT),endothelin-1 and nesfatin plasma concentrations in newly-diagnosed diabetic and non-diabetic patients with metabolic syndrome

Oxytocin (oxt) is implicated as a novel therapy of obesity-diabetes. nesfatin is an anorexigenic adipokine linked to improve insulin sensitivity and dysglycemia in obese/t2dm mice,while endothelin-1 (et-1) is an endothelium vasoconstrictor that is dysregulated in metabolic insulin resistance. the aim of this study was to investigate oxt,et- 1,and nesfatin plasma levels and the correlation between these biomarkers and the various metabolic parameters in the human. in a cross-sectional study,ms-subjects attended the national center for diabetes endocrinology and genetics were enrolled based on their blood glucose levels into (82 ms-non-diabetic vs. 89 ms-pre/diabetic patients). plasma oxt,et-1 and nesfatin levels were measured by competitive binding and sandwich enzyme-linked immunosorbent assays (elisa). when ms-pre/t2dm patients were compared to ms-controls,plasma oxt concentrations (pg/ml) were significantly lower (p < 0.001) (mean ± sd; 1206.28 ± 507.68 vs. 2224 ± 871.22); nesfatin plasma levels (ng/ml) were significantly higher (p < 0.01) (1.04 ± 2.20 vs. 0.31 ± 0.25); while no differences were observed in et-1 (pg/ml) plasma levels (p > 0.05) (4.21 ± 4.19 vs. 4.01 ± 3.51). in conclusion,the present study is the first one which demonstrates an increase in nesfatin concentrations in ms-pre/diabetic patients vs. ms-non-diabetic. our study reported a decrease in oxt levels in ms-pre/t2dm compared to ms-control. besides,et-1 concentrations had no significant difference between non-diabetic and diabetic-ms patients,serum oxt concentrations correlated with several clinical parameters; this is suggestive of oxt as a pharmacologic agent that opposes weight gain and improves insulin resistance. © 2016 dar publishers/the university of jordan. all rights reserved.